Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

GenEdit, a US-based genetic medicine developer based on research at University of California (UC), Berkeley, has completed a $26m series A round featuring the UC-aligned venture capital fund Bow Capital. The round also included pharmaceutical firm Eli Lilly, conglomerate SK, KTB Network, Company K Partners, Korea Investment Partners, Dayli Partners, KB Investment, IMM Investment, TimeFolio…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.